August 19th 2025
The complete response letter (CRL) stated that vatiquinone's new drug application (NDA) did not provide substantial evidence of efficacy and would need to be evaluated in a new trial.
FDA Approves Apomorphine Hydrochloride to Treat Motor Fluctuations in Advanced Parkinson Disease
February 4th 2025The approval marks the first subcutaneous infusion device approved for the treatment of Parkinson disease, providing a new option for patients with serious disease who are unresponsive to other therapies.
Read More
FDA Approves Foscarbidopa/Foslevodopa for Motor Fluctuations in Adults With Parkinson Disease
Published: October 17th 2024 | Updated: October 17th 2024This approval makes foscarbidopa/foslevodopa the first and only subcutaneous 24-hour infusion of levodopa-based therapy for adults with Parkinson disease.
Read More